Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2019

View Archived Issues

Targeted protein degradation with DGY-08-097 shows promise for hepatitis C virus treatment

Discovery and preclinical characterization of c-KIT kinase inhibitor CHMFL-KIT-64

Vulnerable brains can be steered towards healthy development

Four-way interaction screen gives clues to drug effects

FDA clears IND application for phase I/II study of OBI-999

Inhibrx announces phase I dose-escalation data for INBRX-109

Kura Oncology presents phase II results for tipifarnib in HRAS-mutant urothelial carcinoma

Positive phase II data presented for CTP-543 in patients with alopecia areata

TAS-4464 demonstrates potent antitumor activity in hematologic and solid tumor models

BMS-986235 shows efficacy in preclinical models of heart failure

Fulacimstat does not improve standard of care treatment in CHIARA MIA 2 study

Biogen explores non-covalent activation of NRF2 for neurodegenerative and other disorders

Machine learning from adversity speeds compound development

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Pfizer synthesizes new KRAS inhibitors

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Medshine Discovery divulges kynurenine production inhibitors

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Beijing Scitech-Mq Pharmaceuticals describes RET and VEGFR2 inhibitors

InnoCare Pharma identifies TRK inhibitors